National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Government

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

293

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

11 drugs in development

Approved1

Phase 32

Phase 210

Phase 11

Preclinical3

By Therapeutic Area

top 5

Metabolic & Endocrine

320%

Infectious Disease

213%

Nephrology

213%

Oncology

213%

Rare Disease

17%

R&D Momentum

75/100

Pipeline Velocity

41/100

Trial Completion Rate

88/100

Pipeline Concentration

21/100

Pipeline Freshness

0/100

Strategic Signals

↗Active in Infectious Disease but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Recruiting

Diet Order Effects of Low Fat vs. Low Carb Diets on Body Fat Change

Jul 14, 2026

Recruiting

Ketoconazole Effects on Cortisol Circadian Rhythm in Mild Autonomous Cortisol Secretion: A Pilot Study

Jul 14, 2026

Recruiting

Mechanisms in Hepatic Lipid Metabolism in Alcohol Use Disorder: From Genomics, Transcriptomics to Metabolomics

Jul 11, 2026

Completed

Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Infectious Disease(2 drugs)

—

Infectious Disease(2 drugs)

Metabolic & Endocrine(3 drugs)

—

Metabolic & Endocrine(3 drugs)

Nephrology(2 drugs)

—

Nephrology(2 drugs)

Oncology(2 drugs)

—

Oncology(2 drugs)

Rare Disease(1 drug)

—

Rare Disease(1 drug)

Unknown / Other(5 drugs)

—

Unknown / Other(5 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)